Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Read More Share:linkedin| twitter| email

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More Share:linkedin| twitter| email

Dec

03

Unleashing the Power of Digital Solutions in Epilepsy Care

UCB’s Head of Digital Business Transformation, Colin Lake speaks to the current landscape in digital business transformation and neurology.

Read More Share:linkedin| twitter| email

Dec

03

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care

Read More Share:linkedin| twitter| email

Dec

02

Working Toward a More Equitable Future: Addressing Barriers in the Hispanic Epilepsy Community

To better understand the experiences of Hispanic people with epilepsy and to improve our collective effort to break down barriers to equitable health outcomes, UCB is working with patients and their families, as well as health equity experts. Learn more.

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)